Servier
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
AmoyDx, Servier Partner to Develop CDx for Diffuse Glioma in China
The companies will develop a test to detect isocitrate dehydrogenase 1 and 2 gene mutations for use with Servier's investigational drug vorasidenib.
Abbott PCR Test Gets FDA Approval as CDx for Servier's Tibsovo for Rare Blood Cancer
The drug and test were approved for patients with relapsed or refractory myelodysplastic syndromes.
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.